Longeveron (LGVN) Non Operating Income (2020 - 2026)
Longeveron (LGVN) recorded quarterly Non Operating Income of $39000.0 in Q1 2026, down 25.0% quarter-over-quarter from $52000.0 in Q4 2025, and down 77.06% on a YoY basis from $170000.0 in Q1 2025.
Longeveron (LGVN) Non Operating Income (2020 - 2026) Analysis & Trends
Longeveron's Non Operating Income history runs 7 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 77.06% year-over-year to $39000.0; the TTM figure through Mar 2026 stood at $549000.0 (down 20.09% YoY), while the FY2025 annual figure was $680000.0, up 23.86% from the prior year.
- Non Operating Income was $39000.0 for Q1 2026 at Longeveron, down from $52000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $606000.0 in Q4 2022 to a low of -$1.4 million in Q2 2022.
- Historically, Non Operating Income has averaged -$4352.9 across 5 years, with a median of $69000.0 in 2023.
- Biggest YoY gain for Non Operating Income was 1737.84% in 2022; the steepest drop was 2788.46% in 2022.
- A 5-year view of Non Operating Income shows it stood at $606000.0 in 2022, then plunged by 195.87% to -$581000.0 in 2023, then surged by 134.42% to $200000.0 in 2024, then slumped by 74.0% to $52000.0 in 2025, then decreased by 25.0% to $39000.0 in 2026.
- The last three Non Operating Income figures came in at $39000.0 (Q1 2026), $52000.0 (Q4 2025), and $89000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 39,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 369,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | -581,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 606,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -1.40 Mn |
| Mar 31, 2022 | -116,000.00 |
| Dec 31, 2021 | -37,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 52,000.00 |